Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 144 No. 0304 (2014)

A large cohort of patients with hepatocellular carcinoma in a single European centre: aetiology and prognosis now and in a historical cohort

  • Marion Ganslmayer
  • Alexander Hagel
  • Wolfgang Dauth
  • Steffen Zopf
  • Deike Strobel
  • Volker Mueller
  • Michael Uder
  • Markus F. Neurath
  • Juergen Siebler
DOI
https://doi.org/10.4414/smw.2014.13900
Cite this as:
Swiss Med Wkly. 2014;144:w13900
Published
12.01.2014

Summary

PRINCIPLES: The incidence of hepatocellular carcinoma is rising. However, this is occurring not only in developing nations, but in industrial countries as well. Surveillance programmes, classification systems and therapeutic options have improved, but there is a lack of data regarding their impact on the prognosis of this difficult-to-treat cancer.

MATERIALS AND METHODS: We evaluated 484 patients and reported on disease stage, therapeutic procedures and survival time. Data were compared with a historical cohort treated in the same centre 10 years before.

RESULTS: In this cohort, the main reason for liver disease was alcoholism, although hepatitis B remains the leading cause of hepatocellular carcinoma worldwide. Now, most patients have compensated liver function and hepatocellular carcinoma is diagnosed in the early tumour stages (it was diagnosed in the advanced disease stages in the previous cohort). Overall, median survival time was 62.4 weeks, 1-year survival was 58.6% and 3-year survival was 23.2%. Survival time correlated with the stage of liver disease, tumour stage and with therapeutic options.

CONCLUSION: Surveillance programmes lead to diagnosis in earlier tumour stages. Differentiated classification systems allow individualised therapeutic approaches. Earlier cancer stage and compensated liver function allow combination or sequential therapy, which was nearly impossible some years ago but is an option for most now. Primary liver cancer remains a difficult-to-treat malignancy, but the prognosis has improved remarkably, at least in the western world.

References

  1. World Health Organization: World cancer statistics 2012.
  2. Zidan A, Scherelein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in Iran and worldwide. Hepat Mon. 2012;12:6894–7000.
  3. Ni YH, Chen DS. Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol. 2010;58:296–300.
  4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
  5. The Federeal Ministry of Health, Germany. Drug abuse of teenagers and adolescents in the republic of Germany: alcohol, 2011.
  6. European Association for the Study of the Liver. EASL practice guidelines for the treatment of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
  7. Kim BK, Kim SU, Park JY, Kim Dy, Dang HA, Park MS, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve ptients with hepatocelullar carincoma. Liver Int. 2012;12:1120–7.
  8. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2011;56:397–405.
  9. Tinkle CL, Haas-Kogan D. Hepatocellucar carcicnoma: natural history, current management and emerging tools. Biologics: Targets and Therapy. 2012;6:207–19.
  10. Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany-limitations of the “sickest first”-concept. Transpl Int. 2011;24:91–9.
  11. Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244–50.
  12. Herold C, Radespiel-Troeger, Ganslmayer M, Hahn EG, Schuppan D. Prognosis of a large cohort of HCC patients in a single European centre. Liver Int. 2012;22:23–8.
  13. Dietrich CF, Cui XW, Boozari B, Hocke M, Ignee A. Contrast-enhanced ultrasound (CEUS) in the diagnostic algorithm of hepatocellular and cholangiocellular carcinoma, comments on the AASLD guidelines. Ultraschall Med. 2012;33:S57–66.
  14. Den Winkel M, Nagel D, Sappl J, den Winkel P, Lamerz R, Zeck CJ, et al. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging sytems in a large western HCC cohort. Plos One. 2012;10:45066–80.
  15. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9:9739–45.
  16. Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs. 2013;22:141–7.
  17. Fang P, Hu J, Cheng Z, Liu, Z. Wang, K, Jiao S. Efficacy and safety of Bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II Trials. Plos One. 2012;12:49717–25.
  18. Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol. 2013;30:381–8.
  19. Erhardt A, Zhu E, Bondin D, Kubitz R, Knoefel WT, Mödder U, et al. Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: data of a German university clinic. Z Gastroenterol. 2011;49:720–7.
  20. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB. 2005;71:35–41.
  21. Tangutur NK, Medvedev SF, Regenstein F, Balart LA. Hepatocellular carcinoma, a rapidly increasing public health problem: the Tulane experience 2003–2009. J LA State Med Soc. 2011;163:185–90.
  22. Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013;11:95–101.
  23. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol. 2010;9:119-2.
  24. Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl. 2012;18:434–43.
  25. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. OLT for HCC Consensus Group: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:70175–9.
  26. Shao YY, Lu LC, Hsu C, Shen YC, Hsu CH, Cheng AL. Prognosis of advanced hepatocellular carcinoma patients enrolled in cinical trials can be classified by current staging systems. Br J Cancer. 2012;107:1672–7.
  27. Gomez-Rodriguez R, Romera-Gutierrez M, Artaza-Varaza R, Gonzales-Frutos C, Ciampi Dopazo JJ, et al. The value of the Bacelona Clinic Liver Cancer and alpha fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig. 2012;104:298–304.
  28. Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program. Wien Klin Wochenschr. 2011;123:542–51.